Literature DB >> 28321461

[Surgical treatment of metastatic penile cancer - what is the scientific rationale?]

O W Hakenberg1, C Protzel2.   

Abstract

The treatment of metastases of penile cancer is confined to lymphatic metastases. Limited lymph node metastasis in penile cancer can be cured by radical lymph node surgery if complete removal of all lymph nodes of the region is achieved. Adjuvant chemotherapy is recommended. This approach applies to the regional lymph nodes of the inguinal and pelvic regions. Applying this concept to retroperitoneal lymph node metastases may also be reasonable in selected cases. The individual prognosis depends on the extent of lymphatic spread.

Entities:  

Keywords:  Chemotherapy; Groin; Lymph nodes; Node dissection; Sentinel node biopsy

Mesh:

Year:  2017        PMID: 28321461     DOI: 10.1007/s00120-017-0358-8

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  13 in total

1.  Radical excision of the inguinal and iliac lymph glands; a study based upon 450 anatomical dissections and upon supportive clinical observations.

Authors:  E H DASELER; B J ANSON; A F REIMANN
Journal:  Surg Gynecol Obstet       Date:  1948-12

2.  Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis.

Authors:  G Pizzocaro; L Piva
Journal:  Acta Oncol       Date:  1988       Impact factor: 4.089

3.  Radiotherapy for node positive penile cancer: experience of the Leeds teaching hospitals.

Authors:  Kevin N Franks; Kiran Kancherla; Brinda Sethugavalar; Peter Whelan; Ian Eardley; Anne E Kiltie
Journal:  J Urol       Date:  2011-06-22       Impact factor: 7.450

4.  EAU guidelines on penile cancer: 2014 update.

Authors:  Oliver W Hakenberg; Eva M Compérat; Suks Minhas; Andrea Necchi; Chris Protzel; Nick Watkin
Journal:  Eur Urol       Date:  2014-11-01       Impact factor: 20.096

5.  Adjuvant chemotherapy is associated with improved overall survival in pelvic node-positive penile cancer after lymph node dissection: a multi-institutional study.

Authors:  Pranav Sharma; Rosa Djajadiningrat; Kamran Zargar-Shoshtari; Mario Catanzaro; Yao Zhu; Nicola Nicolai; Simon Horenblas; Philippe E Spiess
Journal:  Urol Oncol       Date:  2015-06-10       Impact factor: 3.498

Review 6.  Treatment of visceral, unresectable, or bulky/unresectable regional metastases of penile cancer.

Authors:  Curtis A Pettaway; Lance Pagliaro; Christine Theodore; Gabriel Haas
Journal:  Urology       Date:  2010-08       Impact factor: 2.649

Review 7.  Chemotherapy in patients with penile carcinoma.

Authors:  C Protzel; O W Hakenberg
Journal:  Urol Int       Date:  2009-01-20       Impact factor: 2.089

8.  Endoscopic inguinofemoral lymphadenectomy--extended follow-up.

Authors:  Christian Schwentner; Tilman Todenhöfer; Joerg Seibold; Saladin H Alloussi; Johannes Mischinger; Stefan Aufderklamm; Arnulf Stenzl; Georgios Gakis
Journal:  J Endourol       Date:  2012-12-26       Impact factor: 2.942

9.  The relationship between characteristics of inguinal lymph nodes and pelvic lymph node involvement in penile squamous cell carcinoma: a single institution experience.

Authors:  Giovanni Lughezzani; Mario Catanzaro; Tullio Torelli; Luigi Piva; Davide Biasoni; Silvia Stagni; Alessandro Crestani; Andrea Guttilla; Daniele Raggi; Patrizia Giannatempo; Andrea Necchi; Giorgio Pizzocaro; Maurizio Colecchia; Roberto Salvioni; Nicola Nicolai
Journal:  J Urol       Date:  2013-11-18       Impact factor: 7.450

10.  Prophylactic bilateral groin node dissection versus prophylactic radiotherapy and surveillance in patients with N0 and N1-2A carcinoma of the penis.

Authors:  J N Kulkarni; M R Kamat
Journal:  Eur Urol       Date:  1994       Impact factor: 20.096

View more
  1 in total

Review 1.  [Penile cancer: diagnosis and staging].

Authors:  K-D Sievert; D-L Dräger; F-M Köhn; S Milerski; C Protzel; O W Hakenberg
Journal:  Urologe A       Date:  2018-04       Impact factor: 0.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.